TYLER, Texas / May 28, 2025 / Business Wire / NanoVibronix, Inc. (the “Company”) (NASDAQ: NAOV) confirmed that a series of posts made earlier today with respect to a $26 million registered direct offering of common stock of the Company priced at $0.45 under Nasdaq rules was falsely issued by Flash Alert and FintelAlerts. The Company has not priced and is not consummating any registered direct offering. The Company is actively investigating this misinformation and will take necessary actions to protect its stockholders and its reputation.
| Last Trade: | US$1.13 |
| Daily Change: | 0.07 6.60 |
| Daily Volume: | 1,198,623 |
| Market Cap: | US$4.240M |
May 16, 2025 March 14, 2025 February 14, 2025 January 07, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
